TECHNESCAN MAG3
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TECHNESCAN MAG3 (TECHNESCAN MAG3).
TECHNESCAN MAG3 (mertiatide) is a radiopharmaceutical that undergoes renal tubular secretion via the organic anion transporter (OAT) system, allowing dynamic imaging of renal perfusion and function. After intravenous administration, it exhibits rapid clearance from the blood by the kidneys, providing assessment of effective renal plasma flow.
| Metabolism | TECHNESCAN MAG3 is not metabolized; it is excreted unchanged in the urine primarily by tubular secretion. |
| Excretion | Renal: approximately 90% of injected dose excreted by glomerular filtration and tubular secretion within 24 hours; biliary/fecal: <1%. |
| Half-life | Terminal elimination half-life: approximately 2.5 hours in patients with normal renal function; prolonged in renal impairment. |
| Protein binding | Approximately 90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution: 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid. |
| Bioavailability | Not applicable; administered intravenously only, bioavailability 100%. |
| Onset of Action | Intravenous: immediate renal uptake and excretion; peak renal activity at 2-4 minutes post-injection. |
| Duration of Action | Duration: sufficient for complete renogram acquisition (20-30 minutes); renal activity clears within 24 hours. |
185-370 MBq (5-10 mCi) intravenous bolus injection for renal imaging.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required; the radiopharmaceutical is renally eliminated but used for imaging, not therapeutic effect. |
| Liver impairment | No dose adjustment required for hepatic impairment; metabolism is minimal. |
| Pediatric use | Weight-based: 3.7 MBq/kg (0.1 mCi/kg) minimum 37 MBq (1 mCi), maximum 185 MBq (5 mCi), intravenous bolus. |
| Geriatric use | No specific dose adjustment; dosing based on weight and clinical indication; consider reduced renal function only if it affects image quality but not dose. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TECHNESCAN MAG3 (TECHNESCAN MAG3).
| Breastfeeding | Technetium-99m is excreted into breast milk. The amount of radioactivity transferred to the infant is minimal, and the milk-to-plasma (M/P) ratio has not been specifically reported for MAG3. Guidelines suggest interrupting breastfeeding for 4–24 hours after administration to reduce infant radiation exposure. The exact duration should be based on the administered activity and local radiation safety protocols. |
| Teratogenic Risk | Technetium Tc-99m mertiatide (MAG3) is a radiopharmaceutical. The radiation dose to the fetus depends on gestational age and administered activity. The risk of fetal harm from diagnostic radiopharmaceuticals is generally low but should be weighed against the benefit. During the first trimester, the fetal thyroid may accumulate radioiodine if deiodination occurs, though MAG3 is less likely to deiodinate. The International Commission on Radiological Protection recommends considering alternative imaging in pregnant women if possible. The teratogenic risk is considered low at typical diagnostic doses. |
■ FDA Black Box Warning
None. No boxed warning is included in the FDA-approved labeling.
| Serious Effects |
["Absolute: Known hypersensitivity to mertiatide or any component of the formulation."]
| Precautions | ["Radiation exposure: The product is radioactive and should be used with caution in pregnant women, nursing mothers, and children.","Hypersensitivity reactions: Allergic reactions including anaphylaxis have been reported; ensure emergency resuscitation equipment is available.","Renal impairment: Reduced clearance may alter biodistribution and increase radiation dose; consider dose adjustment."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs during and after administration. No specific fetal monitoring is required for diagnostic studies, but ensure appropriate maternal hydration to promote renal excretion. Verify patient pregnancy status before administration. |
| Fertility Effects | No known adverse effects on fertility from diagnostic doses of technetium-99m MAG3. Radiation exposure to reproductive organs is minimal at typical doses. |